Bio-Techne (NASDAQ:TECH – Get Free Report) and Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) are both healthcare companies, but which is the better stock? Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, 41.1% of Nautilus Biotechnology shares are held by insiders. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Techne $1.21 billion 9.35 $73.40 million $0.69 104.77 Nautilus Biotechnology N/A N/A -$59.00 million ($0.45) -2.00Bio-Techne has higher revenue and earnings than Nautilus Biotechnology. Net Margins Return on Equity Return on Assets Bio-Techne 9.05% 13.57% 10.66% Nautilus Biotechnology N/A -37.58% -30.83%SummaryBio-Techne beats Nautilus Biotechnology on 11 of the 13 factors compared between the two stocks.